Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 62

Sort by

Sort Order Select

Journal Articles

The recombinant adjuvant zoster vaccine induces similar immune responses in ruxolitinib-treated patients with myelofibrosis and polycythemia vera

Beatriz Astibia-Mahillo, Valentina Leguizamon, Elena Mateos, Montserrat Torres, Nerea Armenteros, Maria Cristina Luengo-Martínez, Abelardo Fernández-Chávez, Natalia Daza, Miguel Piris-Villaespesa, Javier Lopez Jimenez, Mayte Coiras, Valentín García Gutiérrez

Blood (2025) 146 (Supplement 1): 7273.

https://doi.org/10.1182/blood-2025-7273

Published: 2025

Journal Articles

Toxicity, efficacy, and clinical management of bispecific antibodies in routine clinical practice: A real-world geltamo study in B-cell lymphoma

Mariana Bastos-Oreiro, Gloria Iacoboni, Pablo Manresa, Carolina Martinez, Laura Magnano, Ana Jiménez Ubieto, Sofía Vázquez-Díaz, Maria Jose Rodriguez Salazar, Maria Teresa Busnego Barreto, Raquel Del Campo, Pedro José Paúl Vidaller, Ilda Murillo, Eva Donato, Angel Serna, Hugo Daniel Luzardo Henríquez, Pilar Gomez Prieto, Elena Perez Ceballos, Begona Mendibil, Sergio Ramons, Ana Maria Garcia-Noblejas Moya, Sonia González De Villambrosia, Francisco Javier Diaz Galvez, Javier Lopez Jimenez, Paula Fernandez-Caldas, Antonio Gutierrez, Blanca Sanchez, Nazaret Dominguez, María Civeira Marin, Paola Villafuerte Gutiérrez, Izaskun Zeberio, Irati Ormezabal, Cristina Barrenetxea Lekue, Norma Gutiérrez, Sofia Martin-Consuegra, Samuel Romero Dominguez, Sofia Huerga, Nuria Golbano, Rosalia Riazza, Jose Antonio Hueso García, Pilar Martinez-Barranco, Belen Navarro Matilla, Lucia Villalon Blanco, Paula Ortega Nadal, Ana Torres Tienza, Víctor Navarro Garces, Pau Abrisqueta, Alejandro Martin Garcia-Sancho

Blood (2025) 146 (Supplement 1): 2732.

https://doi.org/10.1182/blood-2025-2732

Published: 2025

Journal Articles

Head-to-head longitudinal comparison of two mass spectrometry-based methods for monitoring monoclonal proteins in multiple myeloma: Analytical and clinical insights from the GEM-CESAR trial

Blood (2025) 146 (Supplement 1): 2238.

https://doi.org/10.1182/blood-2025-2238

Published: 2025

Journal Articles

Epcoritamab combinations demonstrate promising efficacy in patients (pts) with Richter transformation (RT): First results from arms 2B (epcor + lenalidomide [LEN]) and 2C (epcor + R-CHOP) of the phase 1b/2 EPCORE CLL-1 trial

Philip Thompson, Tamar Tadmor, Hans Herluf Bentzen, Raul Cordoba, Sylvia Snauwaert, Neta Goldschmidt, Martin Simkovic, Jacob Christensen, Javier Lopez Jimenez, Ohad Benjamini, Toshihiko Oki, Andrew J. Steele, Marie Holst Mørch, Ernestine Tucker, Rebecca Valentin, Alexey Danilov, Umberto Vitolo

Blood (2025) 146 (Supplement 1): 1015.

https://doi.org/10.1182/blood-2025-1015

Published: 2025

Journal Articles

Prognostic variables associated with the development of cytokine release syndrome after bispecific antibodies in non-Hodgkin lymphoma patients – the geltamo (Spanish Lymphoma Group) experience

Angel Serna, Gloria Iacoboni, Anna Aguilera Romero, Victor Navarro, Carolina Martinez, Pablo Manresa, Laura Magnano, Ana Jiménez Ubieto, Sofía Vázquez-Díaz, Maria Jose Rodriguez Salazar, Maria Teresa Busnego Barreto, Raquel Del Campo, Pedro José Paúl Vidaller, Ilda Murillo, Eva Donato, Hugo Daniel Luzardo Henríquez, Pilar Gomez Prieto, Elena Perez Ceballos, Begona Mendibil, Sergio Ramos, Ana Maria Garcia-Noblejas Moya, Sonia González De Villambrosia, Francisco Javier Diaz Galvez, Javier Lopez Jimenez, Paula Fernández-Caldas, Ruben Fernandez Alvarez, Antonio Gutierrez, Blanca Sanchez, Nazaret Dominguez, María Civeira Marin, Paola Villafuerte Gutiérrez, Iñigo Olazabal, Izaskun Zeberio, Cristina Barrenetxea Lekue, Diego Clavo-Martín, Samuel Romero Dominguez, Sofia Martin-Consuegra, Sofia Huerga, Nuria Golbano, Rosalia Riazza, Jose Antonio Hueso García, Pilar Martinez-Barranco, Belen Navarro Matilla, Lucia Villalon Blanco, Paula Ortega Nadal, Ana Torres Tienza, Alejandro Martin Garcia-Sancho, Mariana Bastos-Oreiro, Pau Abrisqueta

Blood (2025) 146 (Supplement 1): 3737.

https://doi.org/10.1182/blood-2025-3737

Published: 2025

Journal Articles

Early rescue intervention with daratumumab, pomalidomide and dexamethasone (DPd) in high-risk smoldering myeloma (HR-SMM) patients included in the GEM-CESAR treated with carfilzomib, lenalidomide and dexamethasone (KRd)- autologous stem cell transplantation (ASCT)-krd-rd

Blood (2025) 146 (Supplement 1): 371.

https://doi.org/10.1182/blood-2025-371

Published: 2025

Journal Articles

Pre-transplant physical function and sarcopenia assessment in allogeneic stem cell transplant recipients: A cross-sectional analysis from a multidisciplinary program

Blood (2025) 146 (Supplement 1): 7792.

https://doi.org/10.1182/blood-2025-7792

Published: 2025

Journal Articles

Radiation-free therapy for the initial treatment of good prognosis early non-bulky HL, defined by a low metabolic tumor volume and a negative interim PET after 2 chemotherapy cycles. a phase II prospective rafting trial

Kateryna Filonenko, Marco Picardi, Michal Kurlapski, Livio Trentin, Eva Domingo Domenech, Caterina Patti, Ramon Garcia-Sanz, Javier Nuñez Cespedes, Javier Lopez Jimenez, Agnieszka Giza, Stephane Chauvie, Davide Rossi, Andrea Riccardo Filippi, Maria Pirosa, Marta Bednarek, Anna Sureda Balarí, Alessandro Rambaldi, Andrea Gallamini, Jan Maciej Zaucha

Blood (2025) 146 (Supplement 1): 8243.

https://doi.org/10.1182/blood-2025-8243

Published: 2025

Journal Articles

Plasmablastic lymphoma (PBL) comparison between europe - Latin America and validation of the PBL international prognostic index (PBL-IPI): Collaborative study of the lymphoma groups geltamo, gatla and gell

Blood (2025) 146 (Supplement 1): 899.

https://doi.org/10.1182/blood-2025-899

Published: 2025

Journal Articles

ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, Rapidly Controls Inflammation and Improves 2-Month Survival in Treatment-Naïve Malignancy-Associated Hemophagocytic Lymphohistiocytosis

Blood (2024) 144 (Supplement 1): 805.

https://doi.org/10.1182/blood-2024-204230

Published: 2024

Journal Articles

Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (≥75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma

Franck Morschhauser, David Belada, Johannes Duell, Wojciech Jurczak, Tae Min Kim, Won Seog Kim, Takahiro Kumode, Javier López Jiménez, Caressa Meert, Sergio Ortegon Alcaide, Catherine Thieblemont, Yajian Jiang, Mina Khoshdeli, Yanli Wang, Evelyn Guo, Daniela Hoehn, Sherida Woei-A-Jin

Blood (2024) 144 (Supplement 1): 867.

https://doi.org/10.1182/blood-2024-199271

Published: 2024

Journal Articles

A Phase 1b Study of ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, in Patients with Newly Diagnosed and Previously Treated Secondary Hemophagocytic Lymphohistiocytosis

Abhishek Maiti, Naval Daver, Swami P. Iyer, David McCall, Satyen H Gohil, Javier Lopez Jimenez, Hayley Lane, Benjamin Kim, Kim-Hien Dao, Gary Patou, Sandip Panicker, Kelly Covert, Graham Carl Parry, Carl E Allen

Blood (2023) 142 (Supplement 1): 1162.

https://doi.org/10.1182/blood-2023-177795

Published: 2023

Journal Articles

COVID-19 Severity and Survival over Time in Vaccinated Patients with Hematologic Malignancies

Joaquin Martinez Lopez, Javier De La Cruz, Rodrigo Gil-Manso, Celina Benavente Cuesta, Lauren Benito, jose Angel Hernandez, Maria Regina Herraez, Pilar Herrera Puente, Mi Kwon, Keina Quiroz, Andres Arroyo, Adrian Alegre, María Pilar Llamas Sillero, Javier López Jiménez, Pedro Sanchez-Godoy, Rafael F. Duarte, Jose L. Diez Martin, Víctor Jiménez-Yuste, Julio Garcia-Suarez

Blood (2022) 140 (Supplement 1): 7924–7925.

https://doi.org/10.1182/blood-2022-169545

Published: 2022

Journal Articles

Rituximab Maintenance after R-Bendamustine or R-CHOP in First-Line Treatment of Low-Grade Follicular Lymphoma: A Multicentre, Retrospective Study of the Spanih Group Geltamo

Mariana Bastos-Oreiro, Antonio Gutierrez, Almudena Cabero Martínez, Javier López Jiménez, Paola Sandra Villafuerte Gutierrez, Ana Jimenez-Ubieto, Adolfo De La Fuente, Belén Navarro, Maria Stefania Infante, Raul Cordoba, Jaime Perez De Oteyza, Sonia González de Villambrosia, Raquel Del Campo, Daniel Garcia, Antonio Salar, Juan-Manuel Sancho

Blood (2022) 140 (Supplement 1): 3618–3619.

https://doi.org/10.1182/blood-2022-166027

Published: 2022

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation Achieves Long-Term Survival in Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party

Blood (2022) 140 (Supplement 1): 2306–2307.

https://doi.org/10.1182/blood-2022-164637

Published: 2022

Journal Articles

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)

Blood (2022) 140 (Supplement 1): 292–294.

https://doi.org/10.1182/blood-2022-159606

Published: 2022

Journal Articles

Efficacy and Safety of Single-Agent Zandelisib Administered By Intermittent Dosing in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Final Results of the Tidal Phase 2 Study

Andrew D. Zelenetz, Wojciech Jurczak, Vincent Ribrag, Kim M. Linton, Graham P. Collins, Mark Bishton, Javier López Jiménez, Bhagirathbhai Dholaria, Andrea Mengarelli, Tycel J. Phillips, Nagendra Prasad Sungala, Henry Chan, Gerardo Musuraca, Oonagh Sheehy, Junyi Yan, Weiming Xu, Michel Azoulay, Pier Luigi Zinzani

Blood (2022) 140 (Supplement 1): 3595–3597.

https://doi.org/10.1182/blood-2022-165409

Published: 2022

Journal Articles

Impact of the COVID-19 Pandemic on the Incidence Registry of Hematological Neoplasms in the Region of Madrid (Spain). Preliminary Report of 2014-2021

Blood (2022) 140 (Supplement 1): 10965–10966.

https://doi.org/10.1182/blood-2022-167155

Published: 2022

Journal Articles

Analysis of Immunological and Clinical Response to Vaccination Against Sars-COV-2 in Patients with Chronic Myeloid Leukemia

Alejandro ZURDO Castronuño, Miriam Solera Sainero, Magdalena Corona, Monserrat Torres, Guiomar Casado-Fernandez, Fernando Ramos-García, Javier Garcia-Pérez, María Aranzazú Murciano-Antón, María Jesús Blanchard, Juan Marquet Palomanes, Fernando Martin Moro, Mayte Pérez-Olmeida, Javier López Jiménez, Maria Teresa Coiras, Sara Rodriguez-Mora, Valentín Garcia-Gutiérrez

Blood (2022) 140 (Supplement 1): 3923–3924.

https://doi.org/10.1182/blood-2022-169512

Published: 2022

Journal Articles

Laboratory Prognostic Index (LaPI) : Three Laboratory Variables Are Able to Stratify Diffuse Large B-Cell Lymphoma NOS Patients in Prognostic Clusters at Diagnosis

Fernando Martin Moro, Juan Marquet Palomanes, Jesus Villarrubia, Ana Lario Arribas, Alberto Gonzalez Rodriguez, Beatriz Astibia Mahillo, Maria Isabel Delgado Trillo, Claudia Lopez Prieto, Federico Santiago Herrera, Gemma Moreno Jiménez, Valentín Garcia Gutierrez, Jose Antonio Garcia Vela, Javier Lopez Jimenez

Blood (2021) 138 (Supplement 1): 2505.

https://doi.org/10.1182/blood-2021-151025

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The recombinant adjuvant zoster vaccine induces similar immune responses in ruxolitinib-treated patients with myelofibrosis and polycythemia vera

Toxicity, efficacy, and clinical management of bispecific antibodies in routine clinical practice: A real-world geltamo study in B-cell lymphoma

Head-to-head longitudinal comparison of two mass spectrometry-based methods for monitoring monoclonal proteins in multiple myeloma: Analytical and clinical insights from the GEM-CESAR trial

Epcoritamab combinations demonstrate promising efficacy in patients (pts) with Richter transformation (RT): First results from arms 2B (epcor + lenalidomide [LEN]) and 2C (epcor + R-CHOP) of the phase 1b/2 EPCORE CLL-1 trial

Prognostic variables associated with the development of cytokine release syndrome after bispecific antibodies in non-Hodgkin lymphoma patients – the geltamo (Spanish Lymphoma Group) experience

Early rescue intervention with daratumumab, pomalidomide and dexamethasone (DPd) in high-risk smoldering myeloma (HR-SMM) patients included in the GEM-CESAR treated with carfilzomib, lenalidomide and dexamethasone (KRd)- autologous stem cell transplantation (ASCT)-krd-rd

Pre-transplant physical function and sarcopenia assessment in allogeneic stem cell transplant recipients: A cross-sectional analysis from a multidisciplinary program

Radiation-free therapy for the initial treatment of good prognosis early non-bulky HL, defined by a low metabolic tumor volume and a negative interim PET after 2 chemotherapy cycles. a phase II prospective rafting trial

Plasmablastic lymphoma (PBL) comparison between europe - Latin America and validation of the PBL international prognostic index (PBL-IPI): Collaborative study of the lymphoma groups geltamo, gatla and gell

ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, Rapidly Controls Inflammation and Improves 2-Month Survival in Treatment-Naïve Malignancy-Associated Hemophagocytic Lymphohistiocytosis

Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (≥75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma

A Phase 1b Study of ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, in Patients with Newly Diagnosed and Previously Treated Secondary Hemophagocytic Lymphohistiocytosis

COVID-19 Severity and Survival over Time in Vaccinated Patients with Hematologic Malignancies

Rituximab Maintenance after R-Bendamustine or R-CHOP in First-Line Treatment of Low-Grade Follicular Lymphoma: A Multicentre, Retrospective Study of the Spanih Group Geltamo

Allogeneic Hematopoietic Stem Cell Transplantation Achieves Long-Term Survival in Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)

Efficacy and Safety of Single-Agent Zandelisib Administered By Intermittent Dosing in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Final Results of the Tidal Phase 2 Study

Impact of the COVID-19 Pandemic on the Incidence Registry of Hematological Neoplasms in the Region of Madrid (Spain). Preliminary Report of 2014-2021

Analysis of Immunological and Clinical Response to Vaccination Against Sars-COV-2 in Patients with Chronic Myeloid Leukemia

Laboratory Prognostic Index (LaPI) : Three Laboratory Variables Are Able to Stratify Diffuse Large B-Cell Lymphoma NOS Patients in Prognostic Clusters at Diagnosis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only